Everolimus: all 667 studies that test it

Page 4 of 7. Open to participants first (47), then studies with results posted, then the rest; newest registration first within each.

• Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal CarcinomaCompletedNCT00323739Phase 2Results posted
• Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast CancerCompletedNCT00317720Phase 1/2Results posted
• Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic RejectionCompletedNCT00300274Phase 3Results posted
• Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant RecipientsCompletedNCT00251004Phase 3Results posted
• ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant RecipientsCompletedNCT00170846Phase 4Results posted
• Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant PatientsCompletedNCT00154310Phase 4Results posted
• Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant PatientsCompletedNCT00154297Phase 4Results posted
• Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant PatientsCompletedNCT00154284Phase 3Results posted
• RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine CarcinomaCompletedNCT00113360Phase 2Results posted
• Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung CancerCompletedNCT00096486Phase 1/2Results posted
• RAD001 in Recurrent Endometrial Cancer PatientsCompletedNCT00087685Phase 2Results posted
• Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate CancerCompletedNCT00085566Phase 1/2Results posted
• Everolimus and/or Exercise to Prevent Bone Loss in Postmenopausal WomenActive, not recruitingNCT06789900Phase 2
• Everolimus Aging StudyCompletedNCT05835999Phase 2
• Addition of Everolimus to Standard of Care in Carcinoma GallbladderStatus unknownNCT05833815Phase 2/3
• Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast CancerActive, not recruitingNCT05826964Phase 2
• Adjunctive Everolimus Treatment of Refractory EpilepsyStatus unknownNCT05613166Phase 2
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerActive, not recruitingNCT05508906Phase 1
• Randomized Crossover of SVG101(Dispersible Tab. of Everolimus) and Afinitor 5mg in Healthy AdultsCompletedNCT05490095Phase 1
• Precise Therapy for Refractory HER2 Positive Advanced Breast CancerStatus unknownNCT05429684Phase 3
• A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)Active, not recruitingNCT05252585Phase 4
• Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell CarcinomaCompletedNCT05188118Early Phase 1
• Everolimus Trial in Laryngotracheal StenosisCompletedNCT05153668Early Phase 1
• Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell CarcinomaStatus unknownNCT05124431Phase 2
• Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell CancerActive, not recruitingNCT05012371Phase 2
• DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other MalignanciesTerminatedNCT04895748Phase 1
• Efficacy and Safety of CertiroBell® Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant RecipientsStatus unknownNCT04867720Phase 4
• Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)Status unknownNCT04849533Phase 4
• AZD9833 China PK StudyCompletedNCT04818632Phase 1
• The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
• The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus and Leflunomide in Treatment of BK Virus Infection in Kidney Transplantation RecipientActive, not recruitingNCT04542733Not applicable
• An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.Active, not recruitingNCT04395989Phase 2
• Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerStatus unknownNCT04355858Phase 2
• A MolEcularly Guided Anti-Cancer Drug Off-Label TrialActive, not recruitingNCT04185831Phase 2
• Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid TumorsActive, not recruitingNCT03950609Phase 2
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALLActive, not recruitingNCT03740334Phase 1
• A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With GliomasWithdrawnNCT03632317Phase 2
• Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin AnalogueStatus unknownNCT03629847Phase 1/2
• Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.Active, not recruitingNCT03616587Phase 1
• Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway DeficiencyStatus unknownNCT03580239Phase 3
• Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation TherapyTerminatedNCT03578432Early Phase 1
• Liver Transplantation With Tregs at MGHCompletedNCT03577431Phase 1/2
• Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal TransplantsCompletedNCT03415750Phase 4
• Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the ElderlyActive, not recruitingNCT03373903Phase 2
• A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)CompletedNCT03355794Phase 1
• Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/LymphomaCompletedNCT03328104Phase 1
• Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)CompletedNCT03324373Phase 1
• Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene MutationCompletedNCT03285802Phase 2/3
• Twice-daily Tacrolimus and Everolimus Convert to Once-daily Tacrolimus and Everolimus in Liver Transplant RecipientCompletedNCT03256864Phase 4
• Efficacy and Safety of Precision Therapy in Refractory TumorStatus unknownNCT03239015Phase 2
• Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia.CompletedNCT03216967Phase 4
• A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)CompletedNCT03198949Phase 2
• Open-label Study on Treatment of Primary Aldosteronism With EverolimusCompletedNCT03174171Phase 2
• UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib AloneSuspendedNCT03139747Phase 2
• Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)Active, not recruitingNCT03114527Phase 2
• Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS MutationTerminatedNCT03065387Phase 1
• Fosbretabulin With Everolimus in Neuroendocrine Tumors With ProgressionTerminatedNCT03014297Phase 1
• Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical StudyCompletedNCT02970630Phase 2
• TB Host Directed TherapyStatus unknownNCT02968927Phase 2
• Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentActive, not recruitingNCT02962414Phase 3
• A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatCompletedNCT02890069Phase 1
• Topical Everolimus in Patients With Tuberous Sclerosis ComplexWithdrawnNCT02860494Phase 2/3
• Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCTCompletedNCT02812940Phase 2
• A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast CancerCompletedNCT02742051Phase 2
• Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary OriginStatus unknownNCT02695459Phase 2
• Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic OriginActive, not recruitingNCT02687958Phase 2
• Genomics-Based Target Therapy for Children With Relapsed or Refractory MalignancyStatus unknownNCT02638428Phase 2
• Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast CancersStatus unknownNCT02616848Phase 1
• Study of the Combination of CM082 With Everolimus in Patients With mRCCStatus unknownNCT02577458Phase 1
• Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth SyndromeWithdrawnNCT02569125Phase 2
• Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast CancerCompletedNCT02531932Phase 2
• Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer PatientsCompletedNCT02511639Phase 3
• Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot StudyStatus unknownNCT02493465Phase 4
• PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKITerminatedNCT02479490Phase 2
• Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid TumorsCompletedNCT02449538Phase 2
• Phase I Trial of VS-6766 Alone and in Combination With EverolimusCompletedNCT02407509Phase 1
• Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast CancerStatus unknownNCT02404051Phase 3
• Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial CancerActive, not recruitingNCT02397083Phase 2
• Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast CancerCompletedNCT02344550Phase 2
• Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)TerminatedNCT02338570Phase 4
• Combination of Everolimus and Octreotide LAR in Aggressive Recurrent MeningiomasCompletedNCT02333565Phase 2
• Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine ACompletedNCT02328963Phase 4
• Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung CancerActive, not recruitingNCT02321501Phase 1
• Efficacy and Safety of Everolimus in de Novo Kidney Transplant Recipients of ECD or AKI DonorsStatus unknownNCT02314312Phase 3
• Everolimus trIal for Advanced prememopausaL Breast Cancer PatientsStatus unknownNCT02313051Phase 2
• A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With EverolimusCompletedNCT02305810Phase 2
• Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaTerminatedNCT02254239Phase 1
• Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With BevacizumabCompletedNCT02248571Phase 4
• Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)CompletedNCT02248012Phase 2
• Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic CancerCompletedNCT02240719Phase 1
• Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) EradicationStatus unknownNCT02233049Phase 2
• An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver MetastasisCompletedNCT02205515Phase 1/2
• Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive PatientsCompletedNCT02152943Phase 1
• LDE225 + Everolimus in Advanced Gastroesophageal AdenocarcinomaCompletedNCT02138929Phase 1
• The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted RecipientsCompletedNCT02134899Phase 3
• Belatacept for Renal Transplant Recipients With Delayed Graft FunctionTerminatedNCT02134288Early Phase 1
• Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate CancerCompletedNCT02125084Phase 1
• Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II StudyCompletedNCT02113800Phase 2
• Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With ExemestaneStatus unknownNCT02109913Not applicable

← Everolimus overview